BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 35135840)

  • 1. DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer.
    Kurani H; Razavipour SF; Harikumar KB; Dunworth M; Ewald AJ; Nasir A; Pearson G; Van Booven D; Zhou Z; Azzam D; Wahlestedt C; Slingerland J
    Clin Cancer Res; 2022 May; 28(9):1948-1965. PubMed ID: 35135840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALDH1 Cancer Stem Cell Marker as a Prognostic Factor in Triple-Negative Breast Cancer.
    Panigoro SS; Kurnia D; Kurnia A; Haryono SJ; Albar ZA
    Int J Surg Oncol; 2020; 2020():7863243. PubMed ID: 32695508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
    Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
    Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
    Zhou M; Venkata PP; Viswanadhapalli S; Palacios B; Alejo S; Chen Y; He Y; Pratap UP; Liu J; Zou Y; Lai Z; Suzuki T; Brenner AJ; Tekmal RR; Vadlamudi RK; Sareddy GR
    Breast Cancer Res Treat; 2021 Jan; 185(2):343-357. PubMed ID: 33057995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of Histone Methyltransferase, DOT1L, by Matrix Hyaluronan Promotes MicroRNA-10 Expression Leading to Tumor Cell Invasion and Chemoresistance in Cancer Stem Cells from Head and Neck Squamous Cell Carcinoma.
    Bourguignon LY; Wong G; Shiina M
    J Biol Chem; 2016 May; 291(20):10571-85. PubMed ID: 27002147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiproliferative and Antimigration Activities of Fluoro-Neplanocin A via Inhibition of Histone H3 Methylation in Triple-Negative Breast Cancer.
    Byun WS; Kim WK; Yoon JS; Jarhad DB; Jeong LS; Lee SK
    Biomolecules; 2020 Mar; 10(4):. PubMed ID: 32244385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.
    Matossian MD; Burks HE; Elliott S; Hoang VT; Bowles AC; Sabol RA; Wahba B; Anbalagan M; Rowan B; Abazeed ME; Bunnell BA; Moroz K; Miele L; Rhodes LV; Jones SD; Martin EC; Collins-Burow BM; Burow ME
    BMC Cancer; 2019 Mar; 19(1):205. PubMed ID: 30845999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem cell marker aldehyde dehydrogenase 1 (ALDH1)-expressing cells are enriched in triple-negative breast cancer.
    Li H; Ma F; Wang H; Lin C; Fan Y; Zhang X; Qian H; Xu B
    Int J Biol Markers; 2013 Dec; 28(4):e357-64. PubMed ID: 24338721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting CD73 with flavonoids inhibits cancer stem cells and increases lymphocyte infiltration in a triple-negative breast cancer mouse model.
    Mediratta K; El-Sahli S; Marotel M; Awan MZ; Kirkby M; Salkini A; Kurdieh R; Abdisalam S; Shrestha A; Di Censo C; Sulaiman A; McGarry S; Lavoie JR; Liu Z; Lee SH; Li X; Sciumè G; D'Costa VM; Ardolino M; Wang L
    Front Immunol; 2024; 15():1366197. PubMed ID: 38601156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
    Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
    Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC).
    Ma F; Li H; Li Y; Ding X; Wang H; Fan Y; Lin C; Qian H; Xu B
    Medicine (Baltimore); 2017 Apr; 96(14):e6561. PubMed ID: 28383433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun.
    Xie X; Kaoud TS; Edupuganti R; Zhang T; Kogawa T; Zhao Y; Chauhan GB; Giannoukos DN; Qi Y; Tripathy D; Wang J; Gray NS; Dalby KN; Bartholomeusz C; Ueno NT
    Oncogene; 2017 May; 36(18):2599-2608. PubMed ID: 27941886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair.
    Liang DH; Choi DS; Ensor JE; Kaipparettu BA; Bass BL; Chang JC
    Cancer Lett; 2016 Jul; 376(2):249-58. PubMed ID: 27060208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy.
    Sulaiman A; McGarry S; El-Sahli S; Li L; Chambers J; Phan A; Côté M; Cron GO; Alain T; Le Y; Lee SH; Liu S; Figeys D; Gadde S; Wang L
    Mol Cancer Ther; 2019 Oct; 18(10):1755-1764. PubMed ID: 31308079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR.
    Kim S; Park JM; Park S; Jung E; Ko D; Park M; Seo J; Nam KD; Kang YK; Lee K; Farrand L; Kim YJ; Kim JY; Seo JH
    J Exp Clin Cancer Res; 2023 Nov; 42(1):292. PubMed ID: 37924112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-4319 Suppress the Malignancy of Triple-Negative Breast Cancer by Regulating Self-Renewal and Tumorigenesis of Stem Cells.
    Chu J; Li Y; Fan X; Ma J; Li J; Lu G; Zhang Y; Huang Y; Li W; Huang X; Fu Z; Yin Y; Yuan H
    Cell Physiol Biochem; 2018; 48(2):593-604. PubMed ID: 30021199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.